Urothelial Carcinoma Pipeline Summary

DelveInsight’s, “Urothelial Carcinoma - Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Urothelial Carcinoma: Understanding

Urothelial Carcinoma: Overview

Urothelial carcinoma (UC), also known as transitional cell carcinoma, is the predominant histological subtype of bladder cancer and originates from the urothelial lining of the urinary tract, most commonly the bladder. It typically occurs in older adults and is characterized by a strong male predominance, with hematuria being the most common presenting symptom, sometimes accompanied by irritative lower urinary tract symptoms. Disease ranges from non-muscle-invasive urothelial carcinoma, which is often managed with transurethral resection and intravesical therapies such as mitomycin or Bacillus Calmette-Guérin (BCG), to muscle-invasive and metastatic disease, which generally requires more intensive treatment, including chemotherapy, radical cystectomy, radiotherapy, and increasingly, immune checkpoint inhibitors.

The major risk factors associated with urothelial bladder carcinoma (UBC) include tobacco smoking, which is considered the most important established risk factor, as well as occupational exposure to carcinogens, particularly aromatic amines encountered in the dye, paint, petroleum, and metal industries. Environmental exposures such as air pollution, polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), and fine particulate matter (PM2.5) may also contribute to disease risk. In addition, exposure to chlorinated drinking water and chlorinated swimming pools has been associated with UBC. Other reported factors include genetic susceptibility, dietary factors such as processed meat and whole-milk consumption, alcohol intake, certain chemotherapeutic and oral hypoglycemic agents, and prior radiation therapy.

Urothelial carcinoma arises through the progressive accumulation of genetic and epigenetic alterations in urothelial cells, often triggered by carcinogen exposure. Clonal expansion and subsequent mutations drive uncontrolled proliferation, impaired DNA repair, apoptosis resistance, and tumor progression. Low-grade papillary tumors are commonly associated with FGFR3/RAS pathway alterations, whereas high-grade carcinoma in situ and muscle-invasive tumors more frequently involve TP53, RB1, and other cell-cycle abnormalities. Alterations in the PI3K/AKT/mTOR, RTK/RAS/RAF, TERT, and chromatin-remodeling pathways further contribute to tumor growth and progression from non-muscle-invasive to muscle-invasive and metastatic disease. Molecular heterogeneity, including luminal and basal/squamous subtypes, contributes to differences in tumor behavior, prognosis, and treatment response.

The diagnosis of urothelial carcinoma (UC) typically begins with evaluation of hematuria, supported by urinalysis and urinary imaging. Urine cytology is useful, particularly for detecting high-grade tumors and carcinoma in situ, while cystoscopy remains the primary diagnostic procedure for direct visualization of bladder lesions. Suspicious lesions are biopsied or removed through transurethral resection of bladder tumor (TURBT), which provides definitive histopathological confirmation and establishes tumor grade and stage. CT urography or other cross-sectional imaging is subsequently used to evaluate the urinary tract and assess disease extent and potential invasion.

Management of urothelial carcinoma, particularly UTUC, is guided by tumor risk, location, stage, grade, renal function, and patient fitness. Cisplatin-based neoadjuvant chemotherapy may be used in eligible patients with high-risk disease before surgery. Kidney-sparing endoscopic management with ureteroscopy and laser ablation or fulguration is preferred for selected low-risk tumors and considered in patients requiring renal preservation. Radical nephroureterectomy with bladder-cuff excision remains the standard for high-risk or endoscopically unmanageable disease, while distal or segmental ureterectomy may be considered for selected localized tumors.

"Urothelial Carcinoma- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Urothelial Carcinoma pipeline landscape is provided which includes the disease overview and Urothelial Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Urothelial Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Urothelial Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Urothelial Carcinoma.

Urothelial Carcinoma Emerging Drugs Chapters

This segment of the Urothelial Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Urothelial Carcinoma Emerging Drugs

SYS6002: CSPC Pharmaceutical Group / Corbus Pharmaceuticals

SYS6002 (CRB-701), developed by CSPC Pharmaceutical Group, is an investigational Nectin-4–targeting antibody-drug conjugate (ADC) for advanced urothelial carcinoma. It comprises a Nectin-4 monoclonal antibody conjugated to MMAE through a site-specific linker technology designed to improve stability and therapeutic tolerability. The drug is being evaluated in clinical trials for its antitumor activity in advanced urothelial carcinoma, including patients previously treated with ADCs. Currently, the drug is in Phase III clinical trial of Urothelial Carcinoma.

TYRA-300: Tyra Biosciences

TYRA-300 (dabogratinib) is an investigational, orally administered, highly selective FGFR3 inhibitor and the lead precision medicine program derived from Tyra Biosciences’ proprietary SNÅP platform. The molecule is designed to retain activity against treatment-emergent resistance mutations, including the V555 gatekeeper mutation, while providing greater selectivity for FGFR3 over FGFR1 and other FGFR isoforms to potentially reduce off-target toxicities. Currently, the drug is being evaluated in Phase II clinical trial for the treatment of Urothelial Cancer.

BGB-A445: BeOne Medicine

BGB-A445, developed by BeiGene (now BeOne Medicines), is an investigational OX40 agonist monoclonal antibody designed to activate T cells and enhance antitumor immune responses. In urothelial carcinoma, it is being evaluated in combination with tislelizumab, an anti-PD-1 antibody, in a Phase Ib/II study in patients with Urothelial Carcinoma. The study is assessing the combination’s antitumor activity, safety, tolerability, and pharmacokinetics.

FX-909: Flare Therapeutics

FX-909 is a first-in-class, orally available small-molecule inhibitor of PPARG, a key regulator of the luminal lineage, currently being evaluated in patients with locally advanced or metastatic urothelial carcinoma. A randomized Phase Ib study is assessing its safety and efficacy in patients receiving second-line or later treatment to establish the recommended Phase II dose in a biomarker-defined PPARG-high population with unresectable locally advanced or metastatic UC patient population.

Further product details are provided in the report……..

Urothelial Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Urothelial Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Urothelial Carcinoma
• There are approx. 40+ key companies which are developing the therapies for Urothelial Carcinoma. The companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, CSPC Pharmaceutical Group.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Urothelial Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Urothelial Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Urothelial Carcinoma drugs.

Urothelial Carcinoma Report Insights

• Urothelial Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Urothelial Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Urothelial Carcinoma drugs?
• How many Urothelial Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Urothelial Carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Urothelial Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Urothelial Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CSPC Pharmaceutical Group
• Corbus Pharmaceuticals
• Shanghai Hengrui Pharmaceutical Co., Ltd.
• mabwell Biosciences
• Flare Therapeutics
• Eli Lily and Company
• Tyra Biosciences
• Beone
• Deciphera Pharmaceuticals
• BicycleTx Limited
• SystImmune / Bristol Myers Squibb
• Abbvie
• Nurix Therapeutics,
• Neonc Technologies, Inc.
• Astellas Pharma Global Development
• Biontech
• Inhibrx Biosciences

Key Products

• SYS6002
• SHR-A2102
• 9MW2821
• FX-909
• LY-4052031
• TYRA-300
• BGB-A445
• DCC-2812
• BT8009
• BL-B01D1
• Livmoniplimab
• NX-1607
• NEO212
• ASP2998
• BNT329
• INBRX-106